Doctors advocate defining cancers by mutations to improve drug access

This discussion arises amid advances in genetic knowledge, highlighting challenges in treating rare cancers. Some doctors argue that cancers should be classified based on their genetic mutations rather than the tissues where they appear, which could impact drug accessibility for patients with rare cancers.

Originally published by gnews